Business Wire
BRISBANE, Calif., September 14, 2024--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on September 12, 2024, CareDx granted an option to purchase 100,651 shares of CareDx’s common stock (the "Kennedy Inducement Option") and 70,101 restricted stock units (the "Kennedy In